1. Home
  2. EZRA vs VIVS Comparison

EZRA vs VIVS Comparison

Compare EZRA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reliance Global Group Inc. Common Stock

EZRA

Reliance Global Group Inc. Common Stock

N/A

Current Price

$0.17

Market Cap

4.1M

Sector

Finance

ML Signal

N/A

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

HOLD

Current Price

$1.40

Market Cap

4.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EZRA
VIVS
Founded
2013
2007
Country
United States
United States
Employees
40
9
Industry
Specialty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EZRA
VIVS
Price
$0.17
$1.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.5M
53.4K
Earning Date
05-14-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$42.38
Revenue Next Year
N/A
$15.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$1.25
52 Week High
$0.39
$5.30

Technical Indicators

Market Signals
Indicator
EZRA
VIVS
Relative Strength Index (RSI) 40.14 38.12
Support Level $0.17 $1.25
Resistance Level $0.23 $2.21
Average True Range (ATR) 0.02 0.14
MACD -0.00 0.01
Stochastic Oscillator 8.22 7.55

Price Performance

Historical Comparison
EZRA
VIVS

About EZRA Reliance Global Group Inc. Common Stock

Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.

Share on Social Networks: